Payment overview · 2025
General Payments
$743.00
41 reported records · 15 companies
Healthcare provider profile · identity verified
Chan H. Park, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SHAFTER, CA · NPI 1255336665
Verified facts
What the public records show
CMS Open Payments records show Chan H. Park, M.D. received $743.00 in general payments during 2025 across 41 reported records.
Lilly USA, LLC accounted for 22.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 240 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 240 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 198 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $165.88 | 22.3% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $139.57 | 18.8% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $78.57 | 10.6% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $62.66 | 8.4% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $45.50 | 6.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $39.13 | 5.3% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$36.69 | 4.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $32.68 | 4.4% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $30.50 | 4.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.15 | 3.2% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $24.05 | 3.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.50 | 2.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.17 | 2.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.08 | 2.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $6.87 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $743.00 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $131.29 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $97.25 | 9 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $92.71 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $46.86 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $46.86 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $46.86 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $45.50 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $44.17 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $44.17 | 2 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $36.69 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.73 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.40 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $32.68 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $30.50 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $30.50 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $30.50 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $25.58 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $25.58 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.15 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.50 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.55 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $6.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 62 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 240 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 108 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
240 | 48 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
240 | 48 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
198 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
108 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
62 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 913 | 242 |
| Metformin Hcl | Metformin Hcl | 585 | 158 |
| Amlodipine Besylate | Amlodipine Besylate | 521 | 130 |
| Gabapentin | Gabapentin | 441 | 123 |
| Lisinopril | Lisinopril | 428 | 119 |
| Losartan Potassium | Losartan Potassium | 416 | 119 |
| Hydrochlorothiazide | Hydrochlorothiazide | 354 | 85 |
| Glimepiride | Glimepiride | 346 | 77 |
| Omeprazole | Omeprazole | 288 | 78 |
| Simvastatin | Simvastatin | 263 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 260 | 64 |
| Farxiga | Dapagliflozin Propanediol | 247 | 45 |
| Jardiance | Empagliflozin | 240 | 48 |
| Levothyroxine Sodium | Levothyroxine Sodium | 238 | 60 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 234 | 50 |
| Ibuprofen | Ibuprofen | 223 | 66 |
| Trulicity | Dulaglutide | 198 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 194 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 174 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 173 | 39 |
| Tradjenta | Linagliptin | 170 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 157 | 51 |
| Glipizide | Glipizide | 153 | 39 |
| Montelukast Sodium | Montelukast Sodium | 147 | 31 |
| Alprazolam | Alprazolam | 145 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 139 | 54 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 138 | 55 |
| Clopidogrel | Clopidogrel Bisulfate | 128 | 31 |
| Donepezil Hcl | Donepezil Hcl | 123 | 36 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 120 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 116 | 31 |
| Carvedilol | Carvedilol | 114 | 36 |
| Meclizine Hcl | Meclizine Hcl | 109 | 31 |
| Ozempic | Semaglutide | 108 | 19 |
| Sertraline Hcl | Sertraline Hcl | 107 | 24 |
| Furosemide | Furosemide | 98 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 91 | 21 |
| Clonazepam | Clonazepam | 89 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 88 | 24 |
| Meloxicam | Meloxicam | 88 | 25 |
| Enalapril Maleate | Enalapril Maleate | 87 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 85 | 23 |
| Kerendia | Finerenone | 83 | 11 |
| Atenolol | Atenolol | 82 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 82 | 14 |
| Januvia | Sitagliptin Phosphate | 80 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 78 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 78 | 19 |
| Tramadol Hcl | Tramadol Hcl | 76 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 75 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 73 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 16 |
| Potassium Chloride | Potassium Chloride | 63 | 19 |
| Eliquis | Apixaban | 62 | 19 |
| Pregabalin | Pregabalin | 60 | 13 |
| Alendronate Sodium | Alendronate Sodium | 57 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 52 | 19 |
| Finasteride | Finasteride | 50 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 12 |
| Risperidone | Risperidone | 49 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 46 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 45 | 13 |
| Azithromycin | Azithromycin | 43 | 32 |
| Trazodone Hcl | Trazodone Hcl | 43 | 12 |
| Benazepril Hcl | Benazepril Hcl | 41 | suppressed |
| Celecoxib | Celecoxib | 41 | 11 |
| Famotidine | Famotidine | 39 | 13 |
| Nifedipine Er | Nifedipine | 38 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 37 | suppressed |
| Lorazepam | Lorazepam | 37 | 11 |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 35 | suppressed |
| Allopurinol | Allopurinol | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 33 | suppressed |
| Naproxen | Naproxen | 33 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Procto-Med Hc | Hydrocortisone | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Belsomra | Suvorexant | 16 | suppressed |
| Cartia Xt | Diltiazem Hcl | 16 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Lacosamide | Lacosamide | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Levemir | Insulin Detemir | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $743.00 · 41 records | Lilly USA, LLC | ABRYSVO, CAPVAXIVE, COMIRNATY, CREON, Cologuard Collection Kit, ELIQUIS, ENFLONSIA, FREESTYLE LIBRE 3, GARDASIL 9, JARDIANCE, Korlym, LINZESS, MOUNJARO, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SYMPLICITY G3, UBRELVY, VOQUEZNA, Wegovy, XIFAXAN, ZEPBOUND, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error